title: New insights into atypical parkinsonism.
abstract: OBJECTIVE
  Atypical parkinsonian disorders (APDs) comprise a heterogenous group of disorders including multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Based on literature published in 2010, we here review recent advances in the APD field.
  
  
  RESULTS
  Genome-wide association studies have provided robust evidence of increased disease risk conferred by synuclein and tau gene variants in MSA and PSP. Furthermore, advanced imaging tools have been established in the differential diagnosis and as surrogate markers of disease activity in patients with APDs. Finally, although therapeutic options are still disappointing, translational research into disease-modifying strategies has accelerated with the increasing availability of transgenic animal models, particularly for MSA.
  
  
  CONCLUSIONS
  Remarkable progress has been achieved in the field of APDs, and advances in the genetics, molecular biology and neuroimaging of these disorders will continue to facilitate intensified clinical trial activity.
authors.affiliation: Department of Neurology, Medical University, Innsbruck, Austria. gregor.wenning@i-med.ac.at
authors.forename: Gregor K
authors.initials: GK
authors.lastname: Wenning
authors.forename: Florian
authors.initials: F
authors.lastname: Krismer
authors.forename: Werner
authors.initials: W
authors.lastname: Poewe
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D055106:Genome-Wide Association Study; D006801:Humans; D020961:Lewy Body Disease / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D019578:Multiple System Atrophy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D020734:Parkinsonian Disorders / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D013494:Supranuclear Palsy, Progressive / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D051844:alpha-Synuclein / Q000378:metabolism; D016875:tau Proteins / Q000378:metabolism
chemical_list: D051844:alpha-Synuclein; D016875:tau Proteins